The passing of the futility analysis removes a key binary risk for the ASPIRE trial, but no efficacy data were disclosed. The next major catalyst is the mid-2027 topline readout; monitor for any additional pipeline updates or financing needs before then.
Price Chart
Executive Summary
Vicore Pharma announced that the Phase 2b ASPIRE trial of buloxibutid in IPF passed a pre-planned futility analysis, with the iDMC recommending continuation without modification and no safety concerns identified. The 378-patient trial remains on track for 52-week topline results in mid-2027, and the company's cash runway extends into H2 2028, covering the readout.
Key Facts
- Phase 2b ASPIRE trial of buloxibutid in IPF passed pre-planned futility analysis; iDMC recommended continuation without modification
- No safety concerns identified by iDMC
- 378 patients enrolled across over 100 sites in 14 countries
- Topline 52-week results expected in mid-2027
- Cash runway into second half of 2028, covering the readout
- Futility analysis assessed conditional power threshold of 20%; criteria not met
Financial Impact
No financial figures disclosed; cash runway stated as extending into H2 2028
Risk Factors
- No quantitative efficacy data released; interim results may not predict final outcomes
- IPF is a competitive space with existing therapies and other pipeline candidates
- Clinical-stage biotech with no approved products; reliance on single lead program
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-033290 |
| Document: vcre20261022c_6k.htm | 0001437749-26-033290 |
| Document: 0001437749-26-033290-index-headers.html | 0001437749-26-033290 |
| Document: 0001437749-26-033290-index.html | 0001437749-26-033290 |
| Document: 0001437749-26-033290.txt | 0001437749-26-033290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 6-K | $10.51 | awaiting T+20 | — | $9.38 (−10.75%) |
Oct 13, 2026 12d ago | SC 13G | $9.08 | awaiting T+20 | — | $9.38 (+3.30%) |
Sep 30, 2026 25d ago | 6-K | $9.43 | awaiting T+20 | — | $9.38 (−0.53%) |
Jul 6, 2026 15w ago | 6-K | $16.25 $11.40 | ▼ −29.85% | ▼ −29.28% | $9.38 (−42.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers